Street Talk

Biotech HaemaLogiX prepares for ASX debut; taps Ord Minnett, Canaccord

Sarah Thompson, Kanika Sood and Emma Rapaport

Mar 23, 2026 – 7.36pm

HaemaLogiX, an Australian biotech developing immunotherapies for multiple myeloma – a type of blood cancer of plasma cells – is adding its name to the list of companies cautiously making their way to the ASX.

Bianca Ogden, of Platinum Asset Management. — Platinum’s Bianca Ogden has been following the progress of HaemaLogiX for years. Louie Douvis

Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.

Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.

Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.